GlassScriptPhysician profile
Thomas James Baker
NPI 1952981250
$1,293.12
in general payments reported to CMS, 2019-2025
24 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $57.97 · 2024: $179 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,293.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.62 | 2024-2025 | |
| Corium, LLC | $164.44 | 2024-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $108.54 | 2025 | Farxiga, Breztri |
| Abbott Laboratories | $99.83 | 2023-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $84.39 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $69.34 | 2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $64.27 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $62.43 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.62 | 2025 | Jardiance |
| Lilly USA, LLC | $45.97 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $44.50 | 2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $40.33 | 2025 | |
| Dexcom, INC. | $37.18 | 2024-2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $35.21 | 2025 | Nuzyra |
| Vanda Pharmaceuticals INC. | $28.97 | 2025 | Fanapt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $27.93 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $27.27 | 2024 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.76 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $21.82 | 2025 | Spravato |
| Amgen INC. | $19.93 | 2025 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $16.94 | 2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| E.R. Squibb & Sons, L.L.C. | $16.07 | 2023 | Camzyos |
| Axsome Therapeutics, INC. | $16.00 | 2025 | Auvelity |
| Scpharmaceuticals INC. | $14.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.